{"id":84346,"date":"2020-05-25T03:35:20","date_gmt":"2020-05-25T06:35:20","guid":{"rendered":"https:\/\/iclos.global\/eng\/?post_type=product&#038;p=84346"},"modified":"2021-04-21T20:11:18","modified_gmt":"2021-04-21T23:11:18","slug":"tuzdal","status":"publish","type":"product","link":"https:\/\/iclos.global\/eng\/producto\/tuzdal\/","title":{"rendered":"Tuzdal"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=\u00bb0&#8243; overlay_alpha=\u00bb50&#8243; gutter_size=\u00bb3&#8243; column_width_percent=\u00bb100&#8243; shift_y=\u00bb0&#8243; z_index=\u00bb0&#8243; el_class=\u00bbborro-en-producto\u00bb][vc_column width=\u00bb1\/1&#8243;][vc_column_text]<\/p>\n<h3>Principio activo: Trastuzumab<br \/>\nPresentaciones: 440mg x vial liofilizado<\/h3>\n<p>&nbsp;<\/p>\n<h4><\/h4>\n<p><strong>Mecanismo de acci\u00f3n y blancos moleculares (biol\u00f3gicos)<\/strong><\/p>\n<p>Trastuzumab es un anticuerpo monoclonal recombinante humano IgG que reconoce el<br \/>\nreceptor Her2 presente en ciertos tipos tumorales. Al unirse al receptor desencadena la<br \/>\ninterrupci\u00f3n del ciclo celular y la muerte celular programada. Adem\u00e1s, promueve la muerte<br \/>\ncelular a trav\u00e9s del sistema inmune (mediante las c\u00e9lulas Natural Killer).[\/vc_column_text][\/vc_column][\/vc_row][vc_row row_height_percent=\u00bb0&#8243; overlay_alpha=\u00bb50&#8243; gutter_size=\u00bb3&#8243; column_width_percent=\u00bb100&#8243; shift_y=\u00bb0&#8243; z_index=\u00bb0&#8243; el_class=\u00bbcatalogo-item\u00bb][vc_column width=\u00bb1\/1&#8243;][vc_row_inner][vc_column_inner width=\u00bb1\/1&#8243;][vc_empty_space empty_h=\u00bb0&#8243;][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=\u00bb5\/6&#8243;][vc_column_text][\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00bb1\/6&#8243;][vc_column_text]<img decoding=\"async\" class=\"alignnone wp-image-85422 size-full\" src=\"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2020\/05\/logo-prod.png\" alt=\"\" width=\"128\" height=\"46\" \/>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<h3>Principio activo: Trastuzumab<br \/>\nPresentaciones: 440mg x vial liofilizado<\/h3>\n<p>&nbsp;<\/p>\n<h4><\/h4>\n<p><strong>Mecanismo de acci\u00f3n y blancos moleculares (biol\u00f3gicos)<\/strong><\/p>\n<p>Trastuzumab es un anticuerpo monoclonal recombinante humano IgG que reconoce el receptor Her2 presente en ciertos tipos tumorales. Al unirse al receptor desencadena la interrupci\u00f3n del ciclo celular y la muerte celular programada. Adem\u00e1s, promueve la muerte celular a trav\u00e9s del sistema inmune (mediante las c\u00e9lulas Natural Killer).<\/p>\n<p><strong>Indicaciones terap\u00e9uticas<\/strong><\/p>\n<ul>\n<li>C\u00e1ncer de mama Her2+ en estadios tempranos.<\/li>\n<li>C\u00e1ncer de mama Her2+ metast\u00e1sico.<\/li>\n<li>C\u00e1ncer g\u00e1strico metast\u00e1sico Her2+.<\/li>\n<\/ul>\n<p><strong>Aprobaciones y pautas (FDA; EMA; ASCO; ESMO)<\/strong><\/p>\n<p>Trastuzumab ha sido aprobado por EMA y FDA para las indicaciones<br \/>\nanteriormente mencionadas.<\/p>\n<p><strong>Dosis y plan terap\u00e9utico<\/strong><\/p>\n<p>El plan terap\u00e9utico var\u00eda seg\u00fan la indicaci\u00f3n. La dosis inicial para c\u00e1ncer de mama (precoz o metast\u00e1sico) es de 4mg\/kg por v\u00eda IV, y para c\u00e1ncer g\u00e1strico metast\u00e1sico es de 8mg\/kg v\u00eda IV. Las dosis de mantenimiento var\u00edan entre 2 \u2013 8 mg\/kg con frecuencia semanal o cada 21 d\u00edas seg\u00fan indicaci\u00f3n.<\/p>\n<p><em>Por m\u00e1s informaci\u00f3n ver la ficha t\u00e9cnica del producto.<\/em><\/p>\n","protected":false},"featured_media":85427,"template":"","meta":[],"product_cat":[125],"product_tag":[],"class_list":{"0":"post-84346","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-sin-categorizar","7":"pa_area-terapeutica-biotecnologicos","8":"pa_area-terapeutica-oncologia","9":"pa_nombre-tuzdal","10":"pa_principio-activo-trastuzumab","12":"first","13":"instock","14":"shipping-taxable","15":"product-type-simple"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Tuzdal - ICLOS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/iclos.global\/eng\/producto\/tuzdal\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tuzdal - ICLOS\" \/>\n<meta property=\"og:description\" content=\"Principio activo: Trastuzumab Presentaciones: 440mg x vial liofilizado &nbsp;  Mecanismo de acci\u00f3n y blancos moleculares (biol\u00f3gicos)  Trastuzumab es un anticuerpo monoclonal recombinante humano IgG que reconoce el receptor Her2 presente en ciertos tipos tumorales. Al unirse al receptor desencadena la interrupci\u00f3n del ciclo celular y la muerte celular programada. Adem\u00e1s, promueve la muerte celular a trav\u00e9s del sistema inmune (mediante las c\u00e9lulas Natural Killer).  Indicaciones terap\u00e9uticas   C\u00e1ncer de mama Her2+ en estadios tempranos.  C\u00e1ncer de mama Her2+ metast\u00e1sico.  C\u00e1ncer g\u00e1strico metast\u00e1sico Her2+.  Aprobaciones y pautas (FDA; EMA; ASCO; ESMO)  Trastuzumab ha sido aprobado por EMA y FDA para las indicaciones anteriormente mencionadas.  Dosis y plan terap\u00e9utico  El plan terap\u00e9utico var\u00eda seg\u00fan la indicaci\u00f3n. La dosis inicial para c\u00e1ncer de mama (precoz o metast\u00e1sico) es de 4mg\/kg por v\u00eda IV, y para c\u00e1ncer g\u00e1strico metast\u00e1sico es de 8mg\/kg v\u00eda IV. Las dosis de mantenimiento var\u00edan entre 2 \u2013 8 mg\/kg con frecuencia semanal o cada 21 d\u00edas seg\u00fan indicaci\u00f3n.  Por m\u00e1s informaci\u00f3n ver la ficha t\u00e9cnica del producto.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/iclos.global\/eng\/producto\/tuzdal\/\" \/>\n<meta property=\"og:site_name\" content=\"ICLOS\" \/>\n<meta property=\"article:modified_time\" content=\"2021-04-21T23:11:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2020\/05\/tuzdal.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/iclos.global\/eng\/producto\/tuzdal\/\",\"url\":\"https:\/\/iclos.global\/eng\/producto\/tuzdal\/\",\"name\":\"Tuzdal - ICLOS\",\"isPartOf\":{\"@id\":\"https:\/\/iclos.global\/eng\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/iclos.global\/eng\/producto\/tuzdal\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/iclos.global\/eng\/producto\/tuzdal\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2020\/05\/tuzdal.jpg\",\"datePublished\":\"2020-05-25T06:35:20+00:00\",\"dateModified\":\"2021-04-21T23:11:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/iclos.global\/eng\/producto\/tuzdal\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/iclos.global\/eng\/producto\/tuzdal\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/iclos.global\/eng\/producto\/tuzdal\/#primaryimage\",\"url\":\"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2020\/05\/tuzdal.jpg\",\"contentUrl\":\"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2020\/05\/tuzdal.jpg\",\"width\":600,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/iclos.global\/eng\/producto\/tuzdal\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/iclos.global\/eng\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tienda\",\"item\":\"https:\/\/iclos.global\/eng\/tienda\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Tuzdal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/iclos.global\/eng\/#website\",\"url\":\"https:\/\/iclos.global\/eng\/\",\"name\":\"MEGALABS\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/iclos.global\/eng\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tuzdal - ICLOS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/iclos.global\/eng\/producto\/tuzdal\/","og_locale":"es_ES","og_type":"article","og_title":"Tuzdal - ICLOS","og_description":"Principio activo: Trastuzumab Presentaciones: 440mg x vial liofilizado &nbsp;  Mecanismo de acci\u00f3n y blancos moleculares (biol\u00f3gicos)  Trastuzumab es un anticuerpo monoclonal recombinante humano IgG que reconoce el receptor Her2 presente en ciertos tipos tumorales. Al unirse al receptor desencadena la interrupci\u00f3n del ciclo celular y la muerte celular programada. Adem\u00e1s, promueve la muerte celular a trav\u00e9s del sistema inmune (mediante las c\u00e9lulas Natural Killer).  Indicaciones terap\u00e9uticas   C\u00e1ncer de mama Her2+ en estadios tempranos.  C\u00e1ncer de mama Her2+ metast\u00e1sico.  C\u00e1ncer g\u00e1strico metast\u00e1sico Her2+.  Aprobaciones y pautas (FDA; EMA; ASCO; ESMO)  Trastuzumab ha sido aprobado por EMA y FDA para las indicaciones anteriormente mencionadas.  Dosis y plan terap\u00e9utico  El plan terap\u00e9utico var\u00eda seg\u00fan la indicaci\u00f3n. La dosis inicial para c\u00e1ncer de mama (precoz o metast\u00e1sico) es de 4mg\/kg por v\u00eda IV, y para c\u00e1ncer g\u00e1strico metast\u00e1sico es de 8mg\/kg v\u00eda IV. Las dosis de mantenimiento var\u00edan entre 2 \u2013 8 mg\/kg con frecuencia semanal o cada 21 d\u00edas seg\u00fan indicaci\u00f3n.  Por m\u00e1s informaci\u00f3n ver la ficha t\u00e9cnica del producto.","og_url":"https:\/\/iclos.global\/eng\/producto\/tuzdal\/","og_site_name":"ICLOS","article_modified_time":"2021-04-21T23:11:18+00:00","og_image":[{"width":600,"height":600,"url":"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2020\/05\/tuzdal.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/iclos.global\/eng\/producto\/tuzdal\/","url":"https:\/\/iclos.global\/eng\/producto\/tuzdal\/","name":"Tuzdal - ICLOS","isPartOf":{"@id":"https:\/\/iclos.global\/eng\/#website"},"primaryImageOfPage":{"@id":"https:\/\/iclos.global\/eng\/producto\/tuzdal\/#primaryimage"},"image":{"@id":"https:\/\/iclos.global\/eng\/producto\/tuzdal\/#primaryimage"},"thumbnailUrl":"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2020\/05\/tuzdal.jpg","datePublished":"2020-05-25T06:35:20+00:00","dateModified":"2021-04-21T23:11:18+00:00","breadcrumb":{"@id":"https:\/\/iclos.global\/eng\/producto\/tuzdal\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/iclos.global\/eng\/producto\/tuzdal\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/iclos.global\/eng\/producto\/tuzdal\/#primaryimage","url":"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2020\/05\/tuzdal.jpg","contentUrl":"https:\/\/iclos.global\/eng\/wp-content\/uploads\/2020\/05\/tuzdal.jpg","width":600,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/iclos.global\/eng\/producto\/tuzdal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/iclos.global\/eng\/"},{"@type":"ListItem","position":2,"name":"Tienda","item":"https:\/\/iclos.global\/eng\/tienda\/"},{"@type":"ListItem","position":3,"name":"Tuzdal"}]},{"@type":"WebSite","@id":"https:\/\/iclos.global\/eng\/#website","url":"https:\/\/iclos.global\/eng\/","name":"MEGALABS","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/iclos.global\/eng\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/product\/84346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/media\/85427"}],"wp:attachment":[{"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/media?parent=84346"}],"wp:term":[{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/product_cat?post=84346"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/iclos.global\/eng\/wp-json\/wp\/v2\/product_tag?post=84346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}